Stephen C. Bain MA, MD, FRCPClinical Director, Diabetes Research Unit Cymru, and Medical Director for Research & Development, Swansea Bay University Health Board, Swansea University, Singleton Park, Wales, United Kingdom
Professor Bain completed his undergraduate training at St John's College, Cambridge, and then was clinically trained at King's College Hospital, London. On qualifying in 1983, he went on to hold junior appointments in London, the East Midlands, and the West Midlands, UK. His research centred on the genetics of type 1 diabetes, and he was granted a Medical Research Council Lectureship. In 1993, he became a Senior Lecturer/Honorary Consultant Physician at Birmingham Heartlands Hospital, Birmingham, with promotion to Reader in Diabetic Medicine in 1998. Professor Bain became a Fellow of the Royal College of Physicians UK in 1996. Professor Bain was appointed to a newly created Chair in Medicine (Diabetes) in the University of Wales Swansea in 2005. His clinical interests include the genetics of diabetic nephropathy, new therapies for diabetes and the provision of diabetes services within the community. He has been Chief Investigator for several multi-centre trials investigating novel therapies for diabetes.
Professor Bain is the Diabetes Lead Clinician for the Swansea Bay University Health Board and a member of the Wales Diabetes & Endocrine Society (WEDS) executive committee. He chairs the Joint Clinical Research Facility in Swansea and is currently Chair of the National Specialist Advisory Group (NSAG) for Diabetes in Wales.
DisclosuresDr. Bain reports the following:
Speaker Fees: Astra-Zeneka, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Napp, Novo Nordisk, Roche, Sanofi-Aventis.
Advisory Boards: Eli Lilly, Merck Sharp & Dohme, Novo Nordisk.
Expert advice: All-Wales Medicines Strategy Group & the National Institute for Health and Care Excellence (UK)